CURRICULUM VITAE - CampusNet - Università degli Studi di Parma

CURRICULUM VITAE: NICOLA GIULIANI
Nicola Giuliani è nato a Pisa il 11/11/1968 ed è residente a Parma in Strada Nino Bixio n° 60.
Posizione: Professore Associato Confermato in Malattie del Sangue, Università degli Studi di
Parma e Dirigente Medico, U.O. di Ematologia e CTMO, Azienda Ospedaliero-Universitaria
di Parma.
Titoli: Laurea in Medicina e Chirurgia il 9/7/1993 presso l’Università degli Studi di Firenze
con votazione 110 /110 con Lode.
Specializzazione in Medicina Interna il 29/11/1999 presso l’Università degli Studi di Parma
con votazione 50/50 con lode.
“Fellowship “ in Ematologia dal marzo 1999 a settembre 2000 presso il laboratorio di
oncoematologia dell’Istituto Nazionale della Sanità e della Ricerca Medica (INSERM) di
Nantes (Francia), (Prof R. Bataille/JL. Harousseau).
Dottore di Ricerca nel gennaio del 2002 presso l’Università degli Studi di Parma.
Ricercatore universitario in Malattie del Sangue (MED15) dal febbraio 2001. Ricercatore
Universitario Confermato settore MED15 dal Marzo 2005.
Professore di seconda fascia in Malattie del Sangue (MED15), presso Università degli Studi
di Parma, dal Novembre 2010, confermato dall’Aprile 2014.
“Visiting professor” presso la “Division Hematology and Oncology”, University of
Pittsburgh, PA, USA nel 2004 e 2008.
Attività Scientifica.
Presentazioni orali a congressi scientifici internazionali.
Congresso annuale dell’ ASH nel 2001, 2004, 2006, 2009 e 2010 e al congresso annuale
dell’ISEH nel 2003, 2005, 2006, 2007 e 2008 al congresso annuale della Società Europea di
Ematologia (EHA) nel 2002, 2003, 2007. Relatore su invito a numerosi congressi e simposi
nazionali e internazionali.
Letture su invito presso Università, Istituzioni Estere e a Congressi internazionali.
“Multiple Myeloma bone disease: from the pathophysiology to the treatment” (Invited by O.
Sezer), Berlin, Maggio 2007
“Pathophysiology of Multiple Myeloma bone disease”, Harvard Medical School,
Masachussetts General Hospital, Boston, MA (Invited by Dr. Noopur Raje) Luglio 2008
“Pathophysiology of Multiple Myeloma bone disease and the effects of the new drugs on the
bone microenvironment” Centre Pluridisciplinaire d'Oncologie, CFH, Lausanne, Suisse
(Invited by Dr. Nicholas Ketterer, Aprile 2009.
“Pathophysiology of osteoclast activation in Multiple Myeloma”. Institute for Research
in Biomedicine, Bellinzona, Suisse (Invited by Antonio Lanzavecchia), Novembre 2009.
"Eleventh International ABMT Symposium", Arlington, (USA), 2002
“Eurocancer 2008”, Parigi (Francia), 2008
“Eticho Multiple Myeloma 2010 course”, Madrid, Maggio, 2010
“13th International Myeloma Workshop”, Paris, Maggio 2011
Awards.
“Young Investigator Award” dell’ASBMR nel 2001; “Bando Chiara Tassoni” dell’Università
degli Studi di Parma nel 2002, “Travel Grant” dell’ISEH nel 2003 e 2004.
Grants Internazionali.
Junior Award Grant dell’ ”International Myeloma Foundation” nel 2006 per il progetto
intitolato: “Role of Wnt and Runx2 pathways in the inhibitions of osteoblasts in multiple
myeloma patients”
CV NICOLA GIULIANI Luglio 2014
Senior Award Grant dell’ ”International Myeloma Foundation” nel 2009 per il progetto
intitolato: “Study of alterations of bone microenvironment cells in multiple myeloma patients
in relationship with osteolytic bone lesions: identification of potential new therapeutic targets”
Grants nazionali
Principal investigator IG2009-2012 dell “Associazione Italiana Ricerca sul Cancro” (AIRC)
Responsabile di Unità di Ricerca dei progetti MIUR/PRIN nel 2004, 2006 e 2009
Responsabile di Unità di Ricerca progetto AIRC 5 x 1000 del 2010-2015.
Attività di “Peer reviewer”
“Peer reviewer” per le seguenti riviste: Blood, Leukemia, Haematologica, Leukemia
Research, Br. J. Haematology, Exp Hematol, J Clin Invest.
“Membership” E’ membro della “International Society of Experimental Hematology”
(ISEH), della ”American Society of Hematology” (ASH), della Società Italiana di Ematologia
Sperimentale (SIES) e della Società Italiana di Ematologia (SIE).
Attività Didattica.
Titolare di Corso e affidatario d’insegnamento presso i Corsi di Laurea in Medicina e
Chirurgia, in Biotecnologie Mediche, Veterinarie e Farmaceutiche, e in Scienze Motorie
dell’Università degli Studi di Parma.
Incaricato d’insegnamento presso le Scuole di Specializzazione in: Ematologia, Oncologia
Medica, Medicina Interna, Dermatologia e Venerologia, Ginecologia ed Ostetricia, Malattie
Infettive e Endocrinologia e Malattie del Ricambio.
Docente nel Corso di Dottorato di Ricerca in Scienze Mediche.
Coordinatore del Master in “Cellule Staminali Ematopoietiche e Medicina Rigenerativa”
dell’Università degli Studi di Parma.
Pubblicazioni in esteso su riviste scientifiche internazionali con referee.
Numero di pubblicazioni in “extenso”: 83; Impact factor (IF) totale: 490 (media: 5.9), IF
primo e ultimo nome: 292 (media: 6.5), H-index: 28.
Attività Clinica
Attività clinica di reparto. Day Hospital e Ambulatorio in particolare del paziente con
mieloma multiplo. Gestione di protocolli clinici del gruppo GIMEMA-Mieloma secondo le
regole della “good clinical practise”
CV NICOLA GIULIANI Luglio 2014
LISTA DELLE PUBBLICAZIONI “IN EXTENSO” ULTIMI 15 ANNI.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Quarona V, Ferri V, Chillemi A, Bolzoni M, Mancini C, Zaccarello G, Roato I, Morandi F,
Marimpietri D, Faccani G, Martella E, Pistoia V, Giuliani N, Horenstein AL, Malavasi F.
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow
niche. Ann N Y Acad Sci. 2014 Jul 21. doi: 10.1111/nyas.12485. [Epub ahead of print] [IF:
4.36].
Manni S, Toscani D, Mandato E, Brancalion A, Quotti Tubi L, Macaccaro P, Cabrelle A,
Adami F, Zambello R, Gurrieri C, Semenzato G, Giuliani N, Piazza F. Bone marrow stromal
cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase
CK2. Leukemia. 2014 Jun 4. doi: 10.1038/leu.2014.178. [Epub ahead of print] [IF: 10.16].
Chillemi A, Zaccarello G, Quarona V, Lazzaretti M, Martella E, Giuliani N, Ferracini R,
Pistoia V, Horenstein AL, Malavasi F. CD38 and bone marrow microenvironment. Front
Biosci (Landmark Ed). 2014 Jan 1;19:152-62. [IF: 3.28].
Giuliani N, Dalla Palma B, Bolzoni M. Bisphosphonates in multiple myeloma: Preclinical
and clinical data. Clin Rev Bone Miner Metab. 2013 11(3-4): 113-121.
Silbermann R, Bolzoni M, Storti P, Guasco D, Bonomini S, Zhou D, Wu J, Anderson JL,
Windle JJ, Aversa F, Roodman GD, Giuliani N. Bone marrow monocyte/macrophage derived
activin a mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia. 2013
2014 Apr;28(4):951-4. [IF: 10.16].
Mazzera L, Lombardi G, Abeltino M, Ricca M, Donofrio G, Giuliani N, Cantoni AM,
Corradi A, Bonati A, Lunghi P. Aurora and IKK kinases cooperatively interact to protect
multiple myeloma cells from Apo2L/TRAIL. 2013 Oct 10;122(15):2641-53. [IF: 9.06].
Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M,
La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omedé P,
Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide,
cyclophosphamide and prednisone for relapsed/refractory multiple myeloma: a multicenter
phase 1/2 open label study. Blood. Blood. 2013 Oct 17;122(16):2799-806. [IF: 9.06].
Moschetta M, Basile A, Ferrucci A, Frassanito MA, Rao L, Ria R, Solimando AG, Giuliani
N, Boccarelli A, Fumarola F, Coluccia M, Rossini B, Ruggieri S, Nico B, Maiorano E,
Ribatti D, Roccaro AM, Vacca A. Novel targeting of phospho-cMET overcomes drug
resistance and induces anti-tumor activity in multiple myeloma. Clin Cancer Res. 2013 2013
Aug 15;19(16):4371-82. [IF: 7.83].
Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S,
Liberati AM, Oliva S, Patriarca F, Offidani M, Omedé P, Montefusco V, Petrucci MT,
Giuliani N, Passera R, Pietrantuono G, Boccadoro M, Corradini P, Palumbo A. Bortezomib
induction, reduced-intensity transplantation and lenalidomide consolidation-maintenance for
myeloma: updated results. Blood. 2013 Jun 17. [Epub ahead of print] [IF: 9.06].
Giuliani N, Lisignoli G, Magnani M, Racano C, Bolzoni M, Dalla Palma B, Spolzino A,
Manferdini C, Abati C, Toscani D, Facchini A, Aversa F. New insights into osteogenic and
chondrogenic differentiation of human bone marrow mesenchymal stem cells and their
potential clinical applications for bone regeneration in pediatric orthopaedics. Stem Cells Int.
2013;2013:312501. doi: 10.1155/2013/312501. Epub 2013 May 23.
Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M,
Mancini C, Agnelli L, Patrene K, Maïga S, Franceschi V, Colla S, Anderson J, Neri A, Amiot
M, Aversa F, David Roodman G, Giuliani N. Hypoxia-inducible factor (HIF)-1α suppression
in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.
Leukemia. 2013 Jan 24. doi: 10.1038/leu.2013.24. [Epub ahead of print]. [IF: 10.16].
Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, Agnelli L, Neri A,
Rizzoli V, Giuliani N. Immunomodulatory drugs lenalidomide and pomalidomide inhibit
multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma
microenvironment targeting the expression of adhesion molecules. Exp Hematol. 2012 Nov
23. doi:pii: S0301-472X(12)00542-5. 10.1016/j.exphem.2012.11.005. [Epub ahead of print]
[IF: 2.9].
Bolzoni M, Donofrio G, Storti P, Guasco D, Toscani D, Lazzaretti M, Bonomini S, Agnelli
L, Capocefalo A, Dalla Palma B, Neri A, Nicolini F, Lisignoli G, Russo F, Colla S, Aversa F,
Giuliani N. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human
CV NICOLA GIULIANI Luglio 2014
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic
differentiation impairment induced by myeloma cells. Leukemia. 2013 Feb;27(2):451-63. doi:
10.1038/leu.2012.190. Epub 2012 Jul 11. [IF: 10.16].
Giuliani N, Ferretti M, Bolzoni M, Storti P, Lazzaretti M, Dalla Palma B, Bonomini S,
Martella E, Agnelli L, Neri A, Ceccarelli F, Palumbo C. Increased osteocyte death in multiple
myeloma patients: role in myeloma-induced osteoclast
formation. Leukemia. 2012
Jun;26(6):1391-401. [IF: 10.16].
Kwee I, Rinaldi A, Rancoita P, Rossi D, Capello D, Forconi F, Giuliani N, Piva R, Inghirami
G, Gaidano G, Zucca E, Bertoni F. Integrated DNA copy number and methylation profiling of
lymphoid neoplasms using a single array. Br J Haematol. 2012 Feb;156(3):354-7 [IF: 4.94].
Agnelli L, Storti P, Todoerti K, Sammarelli G, Dalla Palma B, Bolzoni M, Rocci A, Piazza F,
Semenzato G, Palumbo A, Neri A, Giuliani N. Overexpression of HOXB7 and homeobox
genes characterizes multiple myeloma patients lacking the major primary immunoglobulin
heavy chain locus translocations. Am J Hematol. 2011;86:E64-6. [IF: 4.6]
Giuliani N, Airoldi I. Novel insights into the role of interleukin-27 and interleukin-23 in
human malignant and normal plasma cells. Clin Cancer Res. 2011;17:6963-70. [IF: 7.7]
Giuliani N, Storti P, Bolzoni M, Palma BD, Bonomini S. Angiogenesis and Multiple
Myeloma. Cancer Microenviron. 2011 Jul 7.
Storti P, Donofrio G, Colla S, Airoldi I, Bolzoni M, Agnelli L, Abeltino M, Todoerti K,
Lazzaretti M, Mancini C, Ribatti D, Bonomini S, Franceschi V, Pistoia V, Lisignoli G,
Pedrazzini A, Cavicchi O, Neri A, Rizzoli V, Giuliani N. HOXB7 expression by myeloma
cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia.
Leukemia. 2011 Mar;25(3):527-37. [IF: 9.56]
Abeltino M, Bonomini S, Bolzoni M, Storti P, Colla S, Todoerti K, Agnelli L, Neri A, Rizzoli
V, Giuliani N. The proapoptotic effect of zoledronic acid is independent of either the bone
microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced
by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65. [IF: 3.1]
Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, Abeltino M, Ippolito L,
Neri A, Ribatti D, Rizzoli V, Martella E, Giuliani N. Low bone marrow oxygen tension and
hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role
on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia. 2010
Nov;24(11):1967-70 [IF: 8.96]
Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C,Ponzoni M,
Ribatti D, Airoldi I. Interleukin-27 acts as multifunctional antitumor agent in multiple
myeloma. Clin Cancer Res. 2010 Aug 15;16(16):4188-97. Epub 2010 Jun 29. [IF: 6.3]
Giuliani N, Lisignoli G, Novara F, Storti P, Zaffaroni N, Villa R, Sammarelli G, Agnelli L,
Todoerti K, Bernardo ME, Manferdini C, Colla S, Abeltino M, Bolzoni M, Rocci A, Gabusi
E, Palumbo A, Zuffardi O, Neri A, Rizzoli V. Bone osteoblastic and mesenchymal stromal
cells lack of primarily tumoral features in Multiple Myeloma patients. Leukemia. 2010
Jul;24(7):1368-70. [IF: 8.96]
Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S,
Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT,
Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M. Bortezomib as induction before
autologous transplantation, followed by lenalidomide as consolidation-maintenance in
untreated Multiple Myeloma patients. J Clin Oncol. 2010 Feb 10;28(5):800-7. [IF: 18.97]
Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C, Codeluppi K, Colla S,
Crugnola M, Abeltino M, Bolzoni M, Sgobba V, Facchini A, Lambertenghi-Deliliers G,
Zuffardi O, Rizzoli V, Neri A, Giuliani N. Distinct transcriptional profiles characterize bone
microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple
Myeloma bone disease. Exp Hematol. 2010 Feb;38(2):141-53. [IF: 3.20]
Giuliani N, Mangoni M, Rizzoli V. Osteogenic differentiation of mesenchymal stem cells in
Multiple Myeloma: identification of potential therapeutic targets. Exp Hematol. 2009
Aug;37(8):879-86. [IF: 3.20]
Lisignoli G, Codeluppi K, Todoerti K, Manferdini C, Piacentini A, Zini N, Grassi F, Cattini L,
Piva R, Rizzoli V, Facchini A, Giuliani N, Neri A. Gene array profile identifies collagen type
XV as a novel human osteoblast-secreted matrix protein. J Cell Physiol. 2009
Aug;220(2):401-9. [IF: 4.13]
CV NICOLA GIULIANI Luglio 2014
28. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E,
Mezghrani A, Calbi V, Palladini G, Giuliani N, Anderson KC, Sitia R, Cenci S. The
proteasome load versus capacity balance determines apoptotic sensitivity of Multiple
Myeloma cells to proteasome inhibition. Blood. 2009 Mar 26;113(13):3040-9. [IF: 10.43]
29. Desplanques G, Giuliani N, Delsignore R, Rizzoli V, Bataille R, Barillé-Nion S. Impact of
XIAP protein levels on the survival of Myeloma cells. Haematologica. 2009 Jan;94(1):87-93.
[IF: 5.97]
30. Giuliani N, Lisignoli G, Colla S, Lazzaretti M, Storti P, Mancini C, Bonomini S, Manferdini
C, Codeluppi K, Facchini A, Rizzoli V. CC-Chemokine ligand 20/Macrophage inflammatory
protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment
related to osteolytic bone lesions. Cancer Res 2008 Aug 15; 68(16) :6840-6850. [IF: 7.67]
31. Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, Cantoni AM, Salvatore
L, Riccioni R, Costanzo A, Testa U, Levrero M, Rizzoli V, Bonati A. Targeting MEK/MAPK
signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cell
through multiple signaling pathways. Blood 2008; 112 (6): 2450-2462. [IF: 10.89]
32. Airoldi I, Cocco C, Giuliani N, Ferrarini M, Colla S, Ognio E, Taverniti G, Di Carlo E,
Cutrona G, Perfetti V, Rizzoli V, Ribatti D, Pistoia V. Costitutive expression of IL-12RB2 on
human multiple myeloma cells delineates a novel therapeutic target. Blood 2008 Aug
1;112(3):750-759. [IF: 10.89]
33. Maggini V, Buda G, Galimberti S, Conidi E, Giuliani N, Morabito F, Genestreti G, Iacopino
P, Rizzoli V, Barale R, Petrini M, Rossi AM. Response to chemotherapy and tandem
autologous transplantation of multiple myeloma patients and GSTP1 and TYMS
polymorphisms. Leuk Res. 2008 Jan;32(1):49-53. [IF: 2.56]
34. Giuliani N, Rizzoli V. Myeloma cells and bone marrow osteoblast interactions: Role in the
development of osteolytic lesions in multiple myeloma. Leuk Lymphoma. 2007
Dec;48(12):2323-9. [IF: 1.51]
35. Li B, Shi M, Li J, Zhang H, Chen B, Chen L, Gao W, Giuliani N, Zhao RC. Elevated tumor
necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+
mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev. 2007
Dec;16(6):921-30. [IF: 3.22]
36. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D, Mancini C, Lazzaretti
M, Mazzera L, Ravanetti L, Bonomini S, Ferrari L, Miranda C, Ladetto M, Neri TM, Neri A,
Greco A, Mangoni M, Bonati A, Rizzoli V, Giuliani N. The new tumor-suppressor gene
inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic
molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha)
activity: involvement in myeloma-induced angiogenesis. Blood. 2007 Dec 15;110(13):446475. [IF: 10.89]
37. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone
G, Omedè P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foà R, Knight R, Zeldis JB,
Boccadoro M, Petrucci MT; GIMEMA--Italian Multiple Myeloma Network. Melphalan,
prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the
GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol. 2007 Oct 1;25(28):4459-65.
[IF: 15.48]
38. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S, Sala R,
Mangoni M, Rizzoli V. Production of Wnt inhibitors by myeloma cells: potential effects on
canonical Wnt pathway in the bone microenvironment. Cancer Res. 2007 Aug
15;67(16):7665-74. [IF: 7.67]
39. Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F, Genestreti G, Iacopino
P, Rizzoli V, Barale R, Rossi AM, Petrini M. MDR1 polymorphism influences the outcome of
multiple myeloma patients. Br J Haematol. 2007 Jun;137(5):454-6. [IF: 4.49]
40. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, Mancini C,
Martella E, Ferrari L, Tabilio A, Rizzoli V. The proteasome inhibitor bortezomib affects
osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007 Jul
1;110(1):334-8. [IF: 10.89]
41. Giuliani N, Morandi F, Tagliaferri S, Rizzoli V. Targeting pathways mediating bone disease.
Curr Pharm Biotechno. 2006 Dec;7(6):423-9. [IF: 2.75]
CV NICOLA GIULIANI Luglio 2014
42. Giuliani N, Bonomini S, Romagnani P, Lazzaretti M, Morandi F, Colla S, Tagliaferri S,
Lasagni L, Annunziato F, Crugnola M, Rizzoli V. CXCR3 and its binding chemokines in
myeloma cells: expression of isoforms and potential relationships with myeloma cell
proliferation and survival. Haematologica. 2006 Nov;91(11):1489-97. [IF: 5.03]
43. Maggini V, Buda G, Galimberti S, Conidi E, Giuliani N, Morabito F, Genestreti G, Iacopino
P, Rizzoli V, Barale R, Petrini M, Rossi AM. Association of folate transporter SLC19A1
polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem
autologous transplantation. Leukemia. 2007 Jan;21(1):176-8. [IF: 6.92]
44. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: Pathophysiology of
osteoblast inhibition. Blood. 2006 Dec 15;108(13):3992-6. [IF: 10.37]
45. Giuliani N, Morandi F, Tagliaferri S, Colla S, Bonomini S, Sammarelli G, Rizzoli V.
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood.
2006 Jan 15;107(2):841-2. [IF: 10.37]
46. Tosi P, Gamberi B, Giuliani N. Biology and treatment of multiple myeloma. Biol Blood
Marrow Transplant. 2006 Jan;12(1 Suppl 1):81-6. [IF: 3.45]
47. Colla S, Morandi F, Lazzaretti M, Rizzato R, Lunghi P, Bonomini S, Mancini C, Pedrazzoni
M, Crugnola M, Rizzoli V, Giuliani N. Human myeloma cells express the bone regulating
gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple
myeloma patients. Leukemia. 2005 Dec;19(12):2166-76. [IF: 6.61]
48. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S,
Svaldi M, Rizzoli V. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow
osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005 Oct
1;106(7):2472-83. [IF: 10.13]
49. Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, Rizzoli V, Roodman GD,
Giuliani N. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.
Blood. 2005 Aug 15;106(4):1407-14. [IF: 10.13]
50. Giuliani N, Colla S, Morandi F, Barille-Nion S, Rizzoli V. Lack of receptor activator of
nuclear factor-kB ligand (RANKL) expression and functional production by human multiple
myeloma cells. Haematologica. 2005 Feb;90(2):275-8. [IF: 4.57]
51. Giuliani N, Colla S, Morandi F, Rizzoli V. Angiopoietin-1 and myeloma-induced
angiogenesis. Leuk Lymphoma. 2005 Jan;46(1):29-33. [IF: 1.29]
52. Manganelli P, Giuliani N, Fietta P, Mancini C, Lazzaretti M, Pollini A, Quaini F, Pedrazzoni
M. OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the
pathogenetic key? Clin Rheumatol. 2005 Jun;24(3):296-300. [IF: 1.45]
53. Giuliani N, Colla S, Rizzoli V. Angiogenic switch in multiple myeloma. Hematology. 2004
Oct-Dec;9(5-6):377-81. [IF: 1.46]
54. Giuliani N, Colla S, Morandi F, Rizzoli V. The RANK/RANK ligand system is involved in
interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow
microenvironment. Haematologica. 2004 Sep;89(9):1118-23. [IF: 4.19]
55. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and
formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand
(RANKL). Exp Hematol. 2004 Aug;32(8):685-91. [IF: 4.6]
56. Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P, Giuliani N. e6a2 BCR-ABL
transcript in chronic myeloid leukemia: is it associated with aggressive disease?
Haematologica. 2004 May;89(5):611-3. [IF: 4.19]
57. Colla S, Sammarelli G, Crugnola M, Ascani S, Sabbatini E, Bonomini S, Hojden M, Craviotto
L, De Celis I, Morandi F, Caramatti C, Rizzoli V, Giuliani N. Co-existence of Philadelphia
chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of
chronic myeloid leukemia with chronic lymphocytic leukemia. Eur J Haematol. 2004
May;72(5):361-5. [IF: 1.72]
58. Giuliani N, Colla S, Rizzoli V, Barillé-Nion S, Bataille R. Do human myeloma cells directly
produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL
in the bone marrow microenvironment? Cancer Res. 2004 Jan 15;64(2):772-3. [IF: 7.69]
59. Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, Rizzoli V, Bonati A.
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma
cells and myeloma-induced angiogenesis. Leukemia. 2004 Mar;18(3):628-35. [IF: 5.81]
CV NICOLA GIULIANI Luglio 2014
60. Colla S, Morandi F, Lazzaretti M, Polistena P, Svaldi M, Coser P, Bonomini S, Hojden M,
Martella E, Chisesi T, Rizzoli V, Giuliani N. Do human myeloma cells directly produce basic
FGF? Blood. 2003 Oct 15;102(8):3071-2. [IF: 10.12]
61. Colla S, Roti G, Rizzoli V, Giuliani N. Angiopoietins expression by human myeloma cells.
Haematologica. 2003 Jun;88(6):ELT20; author reply ELT21. [IF: 3.45]
62. Giuliani N, Caramatti C, Roti G, Geata A, Colla S, Bonomini S, Hojden M, La Monica S,
Sammarelli G, Lazzaretti M, Craviotto L, Mangoni L, Rizzoli V. Hematologic malignancies
with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary
involvement of the pleura and testes. J Clin Oncol. 2003 May 1;21(9):1887-8. [IF: 10.86]
63. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden
M, Genestreti G, Svaldi M, Coser P, Fattori PP, Sammarelli G, Gazzola GC, Bataille R,
Almici C, Caramatti C, Mangoni L, Rizzoli V. Proangiogenic properties of human myeloma
cells: production of angiopoietin-1 and its potential relationship to myeloma-induced
angiogenesis. Blood. 2003 Jul 15;102(2):638-45. [IF: 10.12]
64. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, Bonomini S, Hojden M,
Sammarelli G, Barillè S, Bataille R, Rizzoli V. Human myeloma cells stimulate the receptor
activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in
multiple myeloma bone disease. Blood. 2002 Dec 15;100(13):4615-21. [IF: 9.63]
65. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barillé S. Myeloma cells induce imbalance
in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.
Blood. 2001 Dec 15;98(13):3527-33. [IF: 9.27]
66. Giuliani N, Sansoni P, Girasole G, Vescovini R, Passeri G, Passeri M, Pedrazzoni M. Serum
interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of
age- and menopause-related changes. Exp Gerontol. 2001 Mar;36(3):547-57. [IF: 2.49]
67. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, Roti E. Serum
concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid
function, ophthalmopathy and cigarette smoking. Eur J Endocrinol. 2000 Aug;143(2):197202. [IF: 2.31]
68. Girasole G, Giuliani N, Modena AB, Passeri G, Pedrazzoni M. Oestrogens prevent the
increase of human serum soluble interleukin-6 receptor induced by ovariectomy in vivo and
decrease its release in human osteoblastic cells in vitro. Clin Endocrinol (Oxf). 1999
Dec;51(6):801-7. [IF: 3.35]
69. Giuliani N, Girasole G, Vescovi PP, Passeri G, Pedrazzoni M. Ethanol and acetaldehyde
inhibit the formation of early osteoblast progenitors in murine and human bone marrow
cultures. Alcohol Clin Exp Res. 1999 Feb;23(2):381-5. [IF: 2.93]
70. Ortalli I, Pedrazzi G, Giuliani N, Cai SZ, Fano V, Ma W, Girasole G, Passeri M. The possible
role of hematin and Mössbauer effect in the inhibition of osteosarcoma cell proliferation.
Anticancer Res. 1998 Nov-Dec;18(6A):4127-30. [IF: 1.33]
71. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates
stimulate formation of osteoblast precursors and mineralized nodules in murine and human
bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice
in vivo. Bone. 1998 May;22(5):455-61. [IF: 3.99]
72. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by
human osteoblast-like cells. Scand J Rheumatol. 1998;27(1):38-41. [IF: 2.27]
Parma 25/07/2014
CV NICOLA GIULIANI Luglio 2014

Download Report